Please check your internet connection and try again.
# Tab%25252525252525252525252525252525252525252525252525252525252520voihep (Sofosbuvir/Velpatasvir)
## Overview
Sofosbuvir/velpatasvir is a fixed-dose combination antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) agent that inhibits viral replication.
## Primary Indications
Chronic hepatitis C virus (HCV) infection in adults. Specific genotype indications and treatment duration may vary based on local guidelines and patient factors.
## Adult Dosing
The standard dose is **one tablet (sofosbuvir 400 mg/velpatasvir 100 mg) orally once daily**. Treatment duration is typically 12 weeks, but may be extended to 24 weeks in certain cases, such as those with cirrhosis or prior treatment failure.
## Pediatric Dosing
Dosing for pediatric patients is not established with this specific combination product.
## Dose Adjustments
No dose adjustments are required for patients with renal impairment. Dose adjustments are not typically necessary for hepatic impairment, but caution is advised in decompensated cirrhosis.
## Contraindications
* Hypersensitivity to sofosbuvir, velpatasvir, or any component of the formulation.
* Use with strong P-glycoprotein (P-gp) inducers such as rifampin and St. John's wort, as this can significantly decrease plasma concentrations of sofosbuvir and velpatasvir, leading to loss of efficacy.
## Adverse Effects
Common adverse effects include headache and fatigue. Less common but significant adverse effects may include bradycardia (especially when coadministered with amiodarone) and potential reactivation of hepatitis B virus (HBV) infection.
## Key Drug Interactions
* **Amiodarone:** Coadministration with sofosbuvir/velpatasvir can lead to severe symptomatic bradycardia. Avoid concomitant use or monitor closely if unavoidable.
* **Strong P-gp inducers (e.g., rifampin, St. John's wort):** Avoid coadministration due to decreased efficacy.
* **Antacids, H2 receptor antagonists, proton pump inhibitors:** May affect absorption of velpatasvir. Separate administration by at least 4 hours for H2 blockers and 12 hours for PPIs.
## Monitoring
* HCV RNA levels to assess treatment efficacy.
* Liver function tests.
* Screening for HBV co-infection prior to initiating therapy.
## Clinical Pearls
* Sofosbuvir/velpatasvir can be used in patients with and without cirrhosis.
* Treatment duration is genotype-dependent and may be influenced by prior treatment history and presence of cirrhosis.
* Always counsel patients on potential drug interactions, particularly with over-the-counter products like St. John's wort.
* Ensure appropriate HBV screening before initiating treatment.
***
*Disclaimer: This information is intended for healthcare professionals and does not replace professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
